Major depressive disorder (MDD) is among the most common diseases of affluence. In recent studies, ghrelin has been linked to some psychiatric conditions: addictive disorders, obsessive-compulsive disorder, schizophrenia, bipolar disorder, and eating disorders (1). Ghrelin’s antagonist, leptin, has also been associated with bipolar disorder or MDD in previous research.

Ghrelin is an orexigenic hormone that primarily regulates food intake, but its many new functions have been discovered in recent years. Ghrelin regulates glucose homeostasis and might play a role in insulin resistance, another condition linked to MDD (2, 3). The hormone also influences lipogenesis and white adipose tissue utilization. Moreover, it was found to protect cardiac muscle during the recovery phase after myocardial infection by reducing sympathetic tonus (4). Ghrelin indirectly enhances the expression of insulin-like growth factor 1 (IGF-1) via growth hormone. The action of IGF-1 on muscle tissue, combined with increased nutrient availability (due to increased appetite), causes ghrelin to induce muscle mass growth. It was also shown that ghrelin induces the proliferation of osteoblasts and increases bone mineral density (4). Moreover, ghrelin mediates inflammation and is connected to sleep-cycle regulation, reward behavior, and memory (5).

Ghrelin binds to the growth hormone secretagogue receptor (GHSR), which is expressed in various organs of the body, including the brain, pancreas, liver, skeletal muscles, and adipose tissue, which explains its pleiotropic mechanism of action (6). Ghrelin is secreted in an inactive-deacylated form, which is later transformed by ghrelin O-acyltransferase to its acylated, active form (7). As a “hunger hormone”, it acts in the pituitary gland and hypothalamus in which it activates orexigenic neuropeptide Y neurons, which initiate appetite (2).

Articles on ghrelin in relation to depressive symptoms were retrieved from databases Academic Search Ultimate, ERIC, Health Source: Consumer Edition, Health Source: Nursing/Academic Edition, and MEDLINE from their inception to August 2023. The keywords were as follows: “depression” OR “depressive disorder” OR “depressive symptoms” OR “major depressive disorder” AND “ghrelin”.

The following inclusion criteria were applied for studies on humans: 1) ghrelin concentration was measured in peripheral blood, 2) patients were diagnosed with or screened for MDD according to the International Classification of Diseases (ICD) or Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria, and 3) all of the participants were adults. Studies were excluded in the following cases: 1) non-English articles, 2) non-original studies, and 3) co-occurrence of chronic disorders.

There are several studies on the relationship between ghrelin concentration in blood and depression among adult, unmedicated participants. Some of the authors reported higher ghrelin levels in those diagnosed with depression (15, 40, 41), while others showed decreased (42) or similar ghrelin levels (43–45) in comparison to healthy participants.

Algul et al. noted that ghrelin concentration shows a positive correlation with the severity of depression. Fasting ghrelin concentration was higher in severely depressed patients in comparison to subjects diagnosed with moderate depression or healthy controls (40).

Ozsoy et al. reported that ghrelin levels were elevated in patients with depression and normalized after treatment with antidepressants, ECT, or both. Furthermore, the method of treatment (drugs vs. ECT vs. drugs + ECT) did not have any influence on the decrease in serum ghrelin concentration (15). Kurt et al. reported the same results among depressed patients treated with ECT (46). The outcomes of the mentioned studies stay consistent with the findings of Ischitobi et al. They demonstrated that ghrelin levels are elevated in patients not responding to 8-week SSRI treatment in comparison to responders and healthy controls (16). Furthermore, Ricken et al. observed that ghrelin levels increase in non-responding patients with MDD after lithium augmentation and decrease in responding patients (47). It could suggest that ghrelin signaling mediates patients’ response to antidepressant treatment.

However, Paslakis et al. did not observe any differences in basal ghrelin concentration before and after antidepressant treatment. However, their study showed changes in ghrelin response to a standardized glucose load procedure (patients received 75 g of glucose after an overnight fasting period, and their ghrelin levels were measured at baseline and after 30, 60, 90, and 120 minutes of glucose intake). A significant difference was observed in terms of the time points of the loading procedure as well as between patients and matched healthy controls. The changes in patients’ BMI and the drug they have taken (mirtazapine vs. venlafaxine) showed no statistically significant influence on ghrelin concentration (48).

Active ghrelin has also been associated with postpartum depression. Baker et al. measured ghrelin levels in the 24-hour urinary samples during pregnancy and 6 weeks after labor. Women screened positive for postpartum depression 12 weeks after childbirth had higher acylated ghrelin concentrations during pregnancy. Moreover, ghrelin levels changed differently in women who were depressed during pregnancy in comparison to non-depressed subjects. The mean change of ghrelin concentration decrease from pregnancy to postpartum was less expressed among women who were depressed during pregnancy. However, the results were not statistically significant when ghrelin levels were adjusted to creatinine. It suggests that renal function should be taken into consideration while planning further research in which ghrelin is measured from urine samples (49).

There is also evidence that ghrelin levels are associated with depression severity among post-menopausal women. Naufel et al. observed that both total and acylated ghrelin concentrations were higher among those with severe depression in comparison to mildly depressed individuals. Both active and total ghrelin levels correlated positively with scores on Beck’s Depression Inventory and Patient Health Questionnaire (50).

Wittekind et al. analyzed data from LIFE-Adult-Study and included 1,092 participants whose total ghrelin levels were measured, and Center for Epidemiologic Studies Depression Scale (CES-D) scores were available. They did not observe any significant difference in regard to ghrelin concentration between depressed and non-depressed subjects. Also, there was no association between CES-D scores and total ghrelin levels (51). It should be noted that the diagnosis of depression was not confirmed by a psychiatrist nor any standardized clinical interview. There are also no data on subjects’ history of using psychotropic drugs or psychiatric evaluations. Mentioned factors could have had an influence on study results, as antidepressant treatment tends to lower ghrelin levels (15, 16, 46).

On the contrary, higher ghrelin levels were associated with a higher prevalence of depression among Japanese women. Akter et al. examined 497 participants (287 men and 210 women). They analyzed the subjects using two different cut-off points for depression in the CES-D scale (≥16 points validated for the general population and ≥19 points validated for the Japanese population). In either setting, the results stayed consistent: there was no association between ghrelin concentration in male subjects, and there was a relationship between higher ghrelin levels and higher odds for the development of depression among women (52).

In a population of older Dutch adults (55 years and older), there was no correlation between total ghrelin concentration and depressive symptoms (assessed with the CES-D scale) at the beginning of the study. However, participants with higher ghrelin levels at baseline had higher odds for depression after 3 years at follow-up, expressed specifically in participants younger than 69.7 years and with a waist–hip ratio below 0.96 (53).

Atescelik et al. conducted a study on patients admitted to the emergency department with recent suicide attempts. They reported that both acylated and unacylated ghrelin levels correlated positively with Beck’s Depression Inventory scores. Both active and non-active ghrelin concentrations were significantly higher in patients than in healthy subjects. Some of the patients had a history of psychiatric conditions (major depressive disorder, schizophrenia, schizo-affective disorder, and personality disorder); however, it did not influence the results of hormone assays between patients with different conditions and patients with no psychiatric history (54).

In recent studies on both animals and humans, ghrelin has been associated with major depressive disorder. This link is expressed in ghrelin’s action involved in stress response and inflammation. The hormone also acts in reward regions of the brain as well as in the amygdala and DRN, regions previously connected to the pathophysiology of MDD. Ghrelin also exhibits some of the antidepressant’s mechanism of action—it influences serotoninergic and glutaminergic transmission and induces synaptic plasticity. Variations in both ghrelin and its receptor genes have also been observed in individuals with depression.

Preclinical studies on animals have revealed that ghrelin influences the results of tests assessing depression-like behavior ( Table 2 ). Researchers have applied many different approaches to evaluate the hypothesis of ghrelin’s antidepressive properties, and therefore, the results are heterogenic and have their limitations. However, it should be noted that in every study in which an animal depression model was induced (by CUMS protocol, disturbed diurnal rhythm, or olfactory bulbectomy), the results stayed consistent, and ghrelin was found as an antidepressive agent independently of the dosage (route of administration, acute vs. chronic). Interestingly, Lutter et al. in the second set of experiments (not included in Table 2 ) did not use exogenous ghrelin but enhanced its endogenic secretion by calorie restriction, and the antidepressive effect persisted. In terms of future research, it would be crucial to induce an animal model of depression in the treated subjects. The promising results from the mentioned preclinical studies should also endorse research on humans.

As ghrelin signaling was shown to interfere with the HPA axis, this connection should also be further evaluated. It may be a key to understanding a mechanism in which ghrelin expresses its anxiolytic mechanism of action observed in animals. There is also a need for future research on ghrelin’s influence on inflammation, as immune response is another factor that contributes to the pathophysiology of MDD, and the data available are limited.

Research on human subjects revealed that antidepressant treatment lowers ghrelin secretion. Moreover, higher levels of circulating ghrelin correlated with the development of depression in the future. Levels of these hormones were also elevated in individuals after suicide attempts and correlated positively with MDD severity among post-menopausal women. Ghrelin was also linked to postpartum depression.

The results of current studies on humans are heterogenic, and therefore, it is difficult to determine their final meaning. The problem might arise from different laboratory methods applied to measure ghrelin levels in participants ( Table 2 ). Ghrelin is characterized by its short half-time, and as a relatively small protein circulating in low concentrations, it is vulnerable to pre-laboratory errors. Hence, the observed dispersion of the results may arise from different laboratory approaches: biological material used (plasma vs. serum), temperature of material storage (−20°C, −70°C, or −80°C), and method applied [enzyme-linked immunosorbent assay (ELISA) or radioimmunoassay (RAI)]. A consistent laboratory approach should be incorporated in future research. Moreover, it would be beneficial if both acylated and deacylated ghrelin were evaluated. This kind of systematic approach would help determine if ghrelin could be a biomarker of depression.

Those results, even if from small sample studies, show that there is a connection between ghrelin and MDD, and it might have clinical consequences. Esketamine is an antidepressant that is recommended for patients with treatment-resistant depression. In studies on animals, ketamine’s action was antagonized by ghrelin administration. Studies on humans revealed that patients with higher BMI, and therefore lower concentration of circulating ghrelin, had a higher chance for remission while being treated with esketamine. On the contrary, among patients treated with escitalopram and venlafaxine, the trend was reversed—those with higher BMI had the lowest remission rate (55). In-depth research on ghrelin signaling and antidepressant treatment could provide insight into treatment resistance mechanism, which still remains a challenge in managing treatment-resistant patients. Moreover, it could determine which antidepressant would be most suitable for a patient in a given metabolic state.

Considering that 20% to 60% of patients do not respond to first-line MDD treatment, broadening the knowledge of biological factors contributing to resistance could shorten the time to recovery. Gathered data suggest that metabolic hormones, including ghrelin, may play a role in treatment response. This possible connection is supported by the fact that ghrelin levels dropped among responders and stayed unchanged among non-responders, as Ischitobi et al. and Ricken et al. have demonstrated. Conducting research that would identify antidepressant medications with a higher response rate in a given metabolic state would benefit both patients and clinicians.

An in-depth understanding of the pathophysiology of depression is highly needed, as it could address some of the problems currently faced by practitioners and patients, which include managing treatment-resistant patients, tolerance to a drug, or weight gain following antidepressant treatment. Future research on the relationship between ghrelin and depression should address the following questions:

ML: Conceptualization, Supervision, Validation, Writing – original draft, Writing – review & editing. TM: Investigation, Writing – original draft, Writing – review & editing. MM: Investigation, Writing – review & editing. TZ: Writing – review & editing.